These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8173192)

  • 1. Catabolism of the tetrapeptide N-Ac-Ser-Asp-Lys-Pro (AcSDKP), an inhibitor of hematopoietic stem cell (CFU-S) proliferation, following in vitro incubation with hematopoietic tissues from normal and leukemic mice.
    Wdzieczak-Bakala J; Grillon C; Robinson S; Riches A; Carde P; Lenfant M
    Bull Cancer; 1993 May; 80(5):391-6. PubMed ID: 8173192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of acetyl-n-ser-asp-lys-pro (AcSDKP) on hematopoietic progenitor cells in short-term and long-term murine bone marrow cultures.
    Jackson JD; Yan Y; Ewel C; Talmadge JE
    Exp Hematol; 1996 Feb; 24(3):475-81. PubMed ID: 8599978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Goralatide (AcSDKP) selectively protects murine hematopoietic progenitors and stem cells against hyperthermic damage.
    Wierenga PK; Konings AW
    Exp Hematol; 1996 Feb; 24(2):246-52. PubMed ID: 8641348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular specificity of action of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) in the control of hematopoietic stem cell proliferation.
    Robinson S; Lenfant M; Wdzieczak-Bakala J; Riches A
    Stem Cells; 1993 Sep; 11(5):422-7. PubMed ID: 8241953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of the adherence of hematopoietic stem cells to mouse bone marrow-derived stromal cell line MS-1-T by a tetrapeptide acetyl-N-Ser-Asp-Lys-Pro.
    Lenfant M; Itoh K; Sakoda H; Sotty D; Sasaki NA; Wdzieczak-Bakala J; Mori KJ
    Exp Hematol; 1989 Sep; 17(8):898-902. PubMed ID: 2767182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Photoprotection of normal human hematopoietic progenitors by the tetrapeptide N-AcSDKP.
    Coutton C; Guigon M; Bohbot A; Ferrani K; Oberling F
    Exp Hematol; 1994 Oct; 22(11):1076-80. PubMed ID: 7925774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological activities of tetrapeptide AcSDKP on hemopoietic cell binding to the stromal cell in vitro.
    Aizawa S; Toyama K; Mori KJ; Frindel E
    Exp Hematol; 1992 Aug; 20(7):896-9. PubMed ID: 1628708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of human bone marrow progenitors by the synthetic tetrapeptide AcSDKP.
    Guigon M; Bonnet D; Lemoine F; Kobari L; Parmentier C; Mary JY; Najman A
    Exp Hematol; 1990 Nov; 18(10):1112-5. PubMed ID: 2209766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of analogues of the tetrapeptide N-Acetyl-Ser-Asp-Lys-Pro (AcSDKP), an inhibitor of primitive haematopoietic cell proliferation.
    Thierry J; Grillon C; Gaudron S; Potier P; Riches A; Wdzieczak-Bakala J
    J Pept Sci; 2001 May; 7(5):284-93. PubMed ID: 11428549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of hematopoiesis in long-term marrow cultures established on adherent layers from AcSDKP-treated dogs.
    Hong DS; Graham T; Ewel C; Storb R; Deeg HJ
    Exp Hematol; 1995 Jul; 23(7):639-44. PubMed ID: 7601256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of leukemic and normal stem cells in leukemic RFM mice.
    Husseini S; Fried W; Knospe WH; Trobaugh FE
    Cancer Res; 1976 May; 36(5):1784-9. PubMed ID: 1268835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced engraftment of intravenously transplanted hematopoietic stem cells into bone marrow of irradiated mice treated with AcSDKP.
    Suzuki A; Aizawa S; Araki S; Hoshi H; Nakano M; Kimura Y; Toyama K
    Exp Hematol; 1998 Jan; 26(1):79-83. PubMed ID: 9430517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The physiological role of the endogenous colony forming units-spleen (CFU-S) inhibitor acetyl-N-Ser-Asp-Lys-Pro (AcSDKP).
    Frindel E; Monpezat JP
    Leukemia; 1989 Oct; 3(10):753-4. PubMed ID: 2779291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tetrapeptide AcSDKP, a physiological inhibitor of normal cell proliferation, reduces the S phase entry of continuous cell lines.
    Volkov L; Quéré P; Coudert F; Comte L; Praloran V
    Exp Cell Res; 1996 Feb; 223(1):112-6. PubMed ID: 8635482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of acetyl-Ser-Asp-Lys-Pro (AcSDKP) on human hematopoietic progenitor cells in short-term and long-term bone marrow cultures.
    Jackson JD; Ozerol E; Yan Y; Ewel C; Talmadge JE
    J Hematother Stem Cell Res; 2000 Aug; 9(4):489-96. PubMed ID: 10982247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo protective effects of tetrapeptide AcSDKP, with or without granulocyte colony-stimulation factor, on murine progenitor cells after sublethal irradiation.
    Watanabe T; Brown GS; Kelsey LS; Yan Y; Jackson JD; Ewel C; Kessinger A; Talmadge JE
    Exp Hematol; 1996 May; 24(6):713-21. PubMed ID: 8635527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory action of the peptide AcSDKP on the proliferative state of hematopoietic stem cells in the presence of captopril but not lisinopril.
    Chisi JE; Wdzieczak-Bakala J; Riches AC
    Stem Cells; 1997; 15(6):455-60. PubMed ID: 9402658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The hemoprotective effect of platelet factor 4 (PF4) and tetrapeptide AcSDKP].
    Han Z; Cai Y; Aidoudi S
    Zhonghua Xue Ye Xue Za Zhi; 1999 Jan; 20(1):33-5. PubMed ID: 11498842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The synthetic tetrapeptide AcSDKP protects cells that reconstitute long-term bone marrow stromal cultures from the effects of mafosfamide (Asta Z 7654).
    Genevay MC; Mormont C; Thomas F; Berthier R
    Exp Hematol; 1996 Jan; 24(1):77-81. PubMed ID: 8536796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further studies on the biological activities of the CFU-S inhibitory tetrapeptide AcSDKP. II. Unresponsiveness of isolated adult rat hepatocytes, 3T3, FDC-P2, and K562 cell lines to AcSDKP. Possible involvement of intermediary cell(s) in the mechanism of AcSDKP action.
    Lauret E; Dumenil D; Miyanomae T; Sainteny F
    Exp Hematol; 1989 Dec; 17(11):1081-5. PubMed ID: 2583252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.